[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100213403":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":22,"centralContacts":26,"locations":35,"responsibleParty":66,"collaborators":10,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":10,"eligibilityCriteria":73,"healthyVolunteers":70,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":80,"studyType":81,"phases":10,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Phoenix Children's Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"10 Patients with sepsis or septic shock",null,"Previously healthy, non-immunocompromised patients, between the ages of 1 and 18, who are being admitted to the PCH PICU for sepsis or septic shock, will be enrolled. Blood samples, urine samples and buccal swabs will be obtained from these patients at 5 time points to analyze biomarkers. Study participants will receive standard of care with antimicrobials and any additional appropriate cardiovascular or respiratory support per the clinical team. The samples will collected and stored at -80 until analysis can be performed. In addition to, during the course of the hospitalization, the enrolled patient will have data collected to calculate severity scores, including PRISM scores and TISS-28 scores. All patient information will be de-identified. A standard procedure manual will be developed detailing the methods for data collection and entry.",[13],"Procedure: miRNA in Sepsis",{"label":15,"type":10,"description":16,"interventionNames":10},"50 Healthy Patients","Healthy non-immunocompromised patients between 1-18 years old",[18],{"type":19,"name":20,"description":20,"armGroupLabels":21,"otherNames":10},"PROCEDURE","miRNA in Sepsis",[9],[23],{"name":24,"affiliation":5,"role":25},"Frederick A Willyerd, MD","PRINCIPAL_INVESTIGATOR",[27,31],{"name":24,"role":28,"phone":29,"phoneExt":10,"email":30},"CONTACT","6029331784","fwillyerd@phoenixchildrens.com",{"name":32,"role":28,"phone":33,"phoneExt":10,"email":34},"Althaia Calla G Ignacio, BSN, MD","6029333795","aignacio@phoenixchildrens.com",[36,57],{"facility":5,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Phoenix","Arizona","85016","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-112.07404,33.44838,{"lat":47,"lon":46},[50,53],{"name":51,"role":28,"phone":52,"phoneExt":10,"email":34},"Althaia Calla G Ignacio","8328007256",{"name":54,"role":28,"phone":55,"phoneExt":10,"email":56},"Aimee LaBell, BSN, MSN","6029335307","alabell@phoenixchildrens.com",{"facility":5,"status":37,"city":38,"state":39,"zip":58,"country":41,"countryCode":42,"cosmosGeoPoint":59,"geoPoint":61,"contacts":62},"85019",{"type":44,"coordinates":60},[46,47],{"lat":47,"lon":46},[63],{"name":64,"role":28,"phone":29,"phoneExt":10,"email":65},"Amit Misra, MD","amisra@phoenixchildrens.com",{"type":67,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100213403","modulation-of-molecular-fingerprinting-in-pediatric-sepsis-100213403",false,"NCT02055105","Modulation of Molecular Fingerprinting in Pediatric Sepsis","Inclusion Criteria:\n\n* Age 1 through 18 years\n* Patients admitted to the PICU with concerns for sepsis or those developing sepsis during their admission to the hospital.\n* Patients must be enrolled int he study from arrival time tot he ED up to 24 hours from the time of initiation of antibiotic therapy for treatment of sepsis or septic shock.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients \\\u003C1 year of age and greater than 18 years of age.","ALL","1 Year","18 Years",{"count":78,"type":79},50,"ESTIMATED","5 Days","OBSERVATIONAL","The goal of this study is to demonstrate the sensitivity and specificity of detecting circulating micro RNA (miRNA) biomarkers in pediatric septic patients. It will also follow expression and modulation of levels in response to therapy in comparison to current biomarkers.",[84],"Systemic Inflammatory Response Syndrome",[86],"Pediatric Sepsis","2025-11-07",{"date":89,"type":90},"2025-11-12","ACTUAL",{"date":92,"type":10},"2014-03",{"date":94,"type":79},"2027-10",{"name":5,"class":6},2]